BusinessSarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXOct 4, 2016, 11:00 AM UTC
BusinessSummit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXSep 27, 2016, 11:00 AM UTC
BusinessSummit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXSep 26, 2016, 11:00 AM UTC
BusinessSummit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy CommunityBy Nasdaq OMXSep 12, 2016, 11:00 AM UTC
BusinessSummit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate EzutromidBy Nasdaq OMXAug 9, 2016, 11:00 AM UTC
BusinessSummit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMDBy Nasdaq OMXMar 30, 2016, 11:00 AM UTC
BusinessSummit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMDBy Nasdaq OMXMar 15, 2016, 11:00 AM UTC
BusinessSummit Therapeutics Supports Ninth Annual Rare Disease DayBy Nasdaq OMXFeb 29, 2016, 12:35 PM UTC
